Shaping the future of medicine with powerful therapeutic and diagnostic platforms
Novel cancer immunotherapies combining Affimer® biotherapeutics and pre|CISION™ Tumour-activated chemotherapy >
Development of high performance Affimer®-based diagnostics to improve health outcomes >
Significant long-term value, growing a pipeline of drug candidates and powerful diagnostic products >
AVA6000 FAP alpha activated prodrug based on the pre|CISIONTM platform.